Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 2:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 393 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Child-Centered Therapy Clear all
Terminated Phase 2 Interventional Results available

Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.

NCT00354172
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
aldesleukin, filgrastim, natural killer cell (NK) therapy, cyclophosphamide, cyclosporine, fludarabine phosphate, methylprednisolone, mycophenolate mofetil, Umbilical Cord Blood Transplantation (UCBT), Total body irradiation (TBI)
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 45 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 25, 2026, 2:42 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Investigate the Efficacy and Safety of Balovaptan (RO5285119) in Participants With Autism Spectrum Disorder (ASD)

NCT02901431
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Placebo, RO5285119
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
5 Years to 17 Years
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
45
States / cities
Dothan, Alabama • Phoenix, Arizona • Orange, California + 41 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Oct 25, 2026, 2:42 AM EDT
Completed Phase 2 Interventional

AT1001 for the Treatment of Long COVID

NCT05747534
View directory record Official record
Conditions
Long COVID, Long COVID-19, Post Acute COVID-19 Syndrome, Post Acute Sequelae of COVID-19
Interventions
Larazotide Acetate, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years to 50 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 25, 2026, 2:42 AM EDT
Active, not recruiting Phase 3 Interventional

Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

NCT05457556
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Busulfan, Cyclophosphamide, Echocardiography Test, Fludarabine, Haploidentical Hematopoietic Cell Transplantation, Lapine T-Lymphocyte Immune Globulin, Lumbar Puncture, Matched Unrelated Donor Hematopoietic Cell Transplantation, Melphalan, Methotrexate, Multigated Acquisition Scan, Mycophenolate Mofetil, Myeloablative Conditioning, Quality-of-Life Assessment, Questionnaire Administration, Rituximab, T-Cell Depletion Therapy, Tacrolimus, Thiotepa, Total-Body Irradiation
Procedure · Drug · Biological + 2 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
6 Months to 21 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
57
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 25, 2026, 2:42 AM EDT
Completed Phase 4 Interventional

The Young Adult and Pediatric Bipolar Study

NCT00350857
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Extended-Release Carbamazepine
Drug
Lead sponsor
Validus Pharmaceuticals
Industry
Eligibility
10 Years to 17 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
26
States / cities
Altamonte Springs, Florida • Fort Lauderdale, Florida • Gainesville, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2014 · Synced Oct 25, 2026, 2:42 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Enhancing Analgesia in Chronic Pain Through Exercise

NCT04862871
View directory record Official record
Conditions
Pain, Chronic Widespread Pain, Fibromyalgia
Interventions
Physical Activity - Pediatric Pain Rehabilitation Center
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
10 Years to 24 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Oct 25, 2026, 2:42 AM EDT
Completed No phase listed Observational

Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65)

NCT02946879
View directory record Official record
Conditions
Leber Congenital Amaurosis (LCA), Eye Diseases, Eye Diseases, Hereditary, Retinal Diseases
Interventions
AAV OPTIRPE65
Biological
Lead sponsor
MeiraGTx UK II Ltd
Industry
Eligibility
3 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Oct 25, 2026, 2:42 AM EDT
Completed Phase 4 Interventional Results available

Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy

NCT01405027
View directory record Official record
Conditions
Chronic Hepatitis C, Genotype 1
Interventions
Educational Intervention, Patient education and management skills training
Procedure · Other
Lead sponsor
Chronic Liver Disease Foundation
Other
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
43
States / cities
Beverly Hills, California • Calabasas, California • Santa Monica, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2015 · Synced Oct 25, 2026, 2:42 AM EDT
Completed Phase 2 Interventional Results available

A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy

NCT01643408
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Interventions
asparaginase Erwinia chrysanthemi
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Year to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
18
States / cities
Los Angeles, California • Orange County, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 25, 2026, 2:42 AM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants

NCT02908685
View directory record Official record
Conditions
Muscular Atrophy, Spinal
Interventions
Placebo, Risdiplam
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 25 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
Palo Alto, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 25, 2026, 2:42 AM EDT
Terminated Phase 3 Interventional

Helping Children With Trauma

NCT02737488
View directory record Official record
Conditions
Trauma, Post-Traumatic Stress Disorder
Interventions
Trauma Systems Therapy (TST), Treatment as Usual (TAU)
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
7 Years to 17 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Oct 25, 2026, 2:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Family Groups for Urban Youth With Disruptive Behavior

NCT02715414
View directory record Official record
Conditions
Mental Disorders
Interventions
Multiple Family Group + Clinic Implementation Team, MFG
Behavioral
Lead sponsor
NYU Silver School of Social Work
Other
Eligibility
18 Years and older
Enrollment
2,956 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 25, 2026, 2:42 AM EDT
Recruiting Not applicable Interventional

Telehealth-Enhanced Asthma Care for Home After the Emergency Room

NCT05844891
View directory record Official record
Conditions
Asthma in Children
Interventions
Telehealth-Enhanced Asthma Care for Home After the Emergency Room (TEACH-ER), Enhanced Care (EC)
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
3 Years to 12 Years
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 25, 2026, 2:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Investigating Interventions to Reduce Residual Opioids in the Home Following Legitimate Opioid Prescribing in Children.

NCT04219397
View directory record Official record
Conditions
Opioid Use, Unspecified
Interventions
Medication take back, Medication home disposal
Other
Lead sponsor
Indiana University
Other
Eligibility
12 Years to 18 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
2
States / cities
Indianapolis, Indiana • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Feb 15, 2024 · Synced Oct 25, 2026, 2:42 AM EDT
Completed Not applicable Interventional

Teletherapy in Children Who Are Deaf and Hard of Hearing

NCT04928209
View directory record Official record
Conditions
Hearing Loss, Speech and Language Development Delay Due to Hearing Loss
Interventions
Speech-Language Teletherapy
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
0 Months to 27 Months
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
5
States / cities
Oakland, California • Palo Alto, California • San Diego, California + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 25, 2026, 2:42 AM EDT
Completed Phase 1 Interventional

Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors

NCT00003597
View directory record Official record
Conditions
Cancer
Interventions
recombinant human thrombopoietin, carboplatin, etoposide, ifosfamide, G-CSF
Biological · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
23
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Oct 25, 2026, 2:42 AM EDT
Approved For Marketing No phase listed Expanded access

Expanded Access of Omegaven IV Fat Emulsion to Infants and Children With PNALD

NCT02929303
View directory record Official record
Conditions
Total Parenteral Nutrition-induced Cholestasis
Interventions
Omegaven IV lipid emulsion
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Up to 17 Years
U.S. locations
1
States / cities
Park Ridge, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 25, 2026, 2:42 AM EDT
Completed Not applicable Interventional Results available

Video-visit Behavior Therapy for Anxiety and Depression in Youth

NCT05417412
View directory record Official record
Conditions
Anxiety, Depression
Interventions
Brief Behavioral Therapy
Behavioral
Lead sponsor
San Diego State University
Other
Eligibility
8 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 25, 2026, 2:42 AM EDT
Completed Phase 3 Interventional

Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy

NCT00151983
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate Transdermal System
Drug
Lead sponsor
Noven Therapeutics
Industry
Eligibility
6 Years to 12 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
18
States / cities
Scottsdale, Arizona • San Marcos, California • Boulder, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2015 · Synced Oct 25, 2026, 2:42 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Clinical Trial of Gene Therapy for the Treatment of Leber Congenital Amaurosis (LCA)

NCT02781480
View directory record Official record
Conditions
Leber Congenital Amaurosis
Interventions
AAV RPE65
Biological
Lead sponsor
MeiraGTx UK II Ltd
Industry
Eligibility
3 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Oct 25, 2026, 2:42 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Amblyopia Treatment for Children Aged 8 to 12 Years

NCT07281742
View directory record Official record
Conditions
Amblyopia
Interventions
Curesight dichoptic videos
Device
Lead sponsor
Retina Foundation of the Southwest
Other
Eligibility
8 Years to 12 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 25, 2026, 2:42 AM EDT
Recruiting No phase listed Observational

A Study on Hemolytic Disease of the Fetus and Newborn (HDFN) Through Global Registry

NCT07194070
View directory record Official record
Conditions
Hemolytic Disease of the Fetus and Newborn
Interventions
Standard of Care
Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
5
States / cities
Indianapolis, Indiana • Rochester, New York • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 25, 2026, 2:42 AM EDT
Completed Not applicable Interventional Results available

Child Characteristics, Neuromarkers, and Intervention Components Impacting Treatment Outcome: CCT, TF-CBT, TAU

NCT02926677
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic
Interventions
Cue-Centered Treatment (CCT), Trauma-Focused CBT (TF-CBT), Treatment as Usual, NIRScout
Behavioral · Device
Lead sponsor
Stanford University
Other
Eligibility
7 Years to 18 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Sacramento, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 25, 2026, 2:42 AM EDT
Terminated Phase 3 Interventional Results available

Canakinumab to Treat Neonatal-Onset Multisystem Inflammatory Disease

NCT00770601
View directory record Official record
Conditions
NOMID, CINCA Syndrome
Interventions
Canakinumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 25 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Oct 25, 2026, 2:42 AM EDT